MarketResearchNest.com adds “Schistosomiasis – Pipeline Review, H2 2017” new report to its research database. The report spread across 40 pages with table and figures in it.
Schistosomiasis – Pipeline Review, H2 2017
Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Schistosomiasis – Pipeline Review, H2 2017, provides an overview of the Schistosomiasis (Infectious Disease) pipeline landscape.
Schistosomiasis is a type of infection caused by parasites that live in fresh water, such as rivers or lakes. Symptoms include a high temperature, headache, cough, a dark red, blotchy, raised skin rash, pain in the abdomen and joint and muscle pain.
Browse full table of contents and data tables at
The Schistosomiasis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Schistosomiasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 2, 5 and 2 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 1 and 1 molecules, respectively.
Schistosomiasis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Companies Involved in Therapeutics Development
Kancera AB, Knight Therapeutics Inc, LondonPharma Ltd, Merck KGaA, Salvensis.
Order a Purchase Report Copy at https://www.marketresearchnest.com/purchase.php?reportid=262571
Featured News & Press Releases
Aug 23, 2013: BioDiem US patent for skin and wound infections
Feb 08, 2013: BioDiem Progresses To Proof-Of-Concept Testing Of BDM-I Antimicrobial Effect Against Parasites
Nov 08, 2012: BioDiem Partners With Griffith University To Enhance Antimicrobial Drug BDM-I
Oct 18, 2012: BioDiem Reports Continued Progress In Development Of Antimicrobial BDM-I
Aug 08, 2012: BioDiem Receives European Patent For Antimicrobial Compound BDM-I
Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective RandD strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Schistosomiasis (Infectious Disease).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Schistosomiasis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Request a sample copy at
MarketResearchNest.com is the most comprehensive collection of market research products and service Schistosomiasis on the Web. We offer reports from almost all top publishers and update our collection on daily basis to provide you with instant online access to the world’s most complete and recent database of expert insights on global industries, organizations, products, and trends.
Mr. Jeet Jain